TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB To Stage IV Cutaneous Melanoma (TuHURA Biosciences)
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, announced that the U.S FDA has granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.